Related Experiment Video

Updated: Jan 2, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

841

An overview of GLP-1 agonists and recent cardiovascular outcomes trials

Kelsey H Sheahan1, Elizabeth A Wahlberg2, Matthew P Gilbert3

  • 1Endocrinology, University of Vermont Medical Center, Burlington, Vermont, USA kelsey.sheahan@uvmhealth.org.

Postgraduate Medical Journal
|December 6, 2019
PubMed

Insights

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) improve type 2 diabetes management by lowering blood sugar and aiding weight loss. Cardiovascular outcomes trials show these drugs are safe and effective, impacting treatment guidelines.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Cardiology

Background:

  • Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are increasingly recognized for managing type 2 diabetes (T2D).
  • Key benefits include reduced glycated hemoglobin, weight loss, and a low risk of hypoglycemia.
  • Recent cardiovascular outcomes trials (CVOTs) have provided critical safety and efficacy data.

Purpose of the Study:

  • To review the therapeutic role of GLP-1 receptor agonists in type 2 diabetes management.
  • To analyze the findings of seven major cardiovascular outcomes trials involving various GLP-1 RAs.
  • To discuss the impact of these findings on current clinical guidelines and future therapeutic strategies.

Main Methods:

  • Systematic review of published literature.
  • Analysis of seven cardiovascular outcomes trials (CVOTs) for GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide, oral semaglutide).
  • Evaluation of trial data regarding cardiovascular events, glycemic control, and adverse events.

Main Results:

  • All seven CVOTs demonstrated non-inferiority for cardiovascular outcomes.
  • Several trials indicated superiority of GLP-1 RAs in reducing cardiovascular events.
  • Consistent benefits in glycemic control and weight management were observed across studies.

Conclusions:

  • GLP-1 RAs represent a significant advancement in type 2 diabetes pharmacotherapy.
  • Evidence from CVOTs supports their use for both glycemic control and cardiovascular risk reduction.
  • These findings necessitate updates to clinical practice guidelines for T2D management.
Keywords:
adult cardiologyclinical pharmacologycoronary heart diseasegeneral diabetes

More Related Videos

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.9K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
786
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
543
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
537
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
482
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
521